

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Daria ONICHTCHOUK et al.

Examiner: Unassigned

Serial No.: 10/564,769

Group Art Unit: Unassigned

Filed: January 17, 2006

Title: USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC

DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME

REQUEST FOR WITHDRAWAL OF IMPROPER HOLDING OF ABANDONMENT

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In view of the following documents, it is unambiguous that Applicants filed a complete response to the missing parts notice dated April 11, 2006. This response was filed on June 12, 2006.

Attached is a copy of the firm's Official PTO filing record notebook for the day of June 12, 2006. Listed in association with the firm's docket number for the above-identified application, "Weickm-0053," is the entry "NTFMR; Decl & POA; Assign; Ck#37127 \$40.00; Record Cover Sheet; Seq. listing w/disk ck#37126 \$65.00." This means that being filed is a response to the notice to file missing requirements; a declaration and a power of attorney; an

assignment (ck#37127 for \$40.00); a recordation cover sheet for the assignment; a sequence listing with disk along with ck#37126 for \$65.00.

The initials in our rightmost margins refer to various personnel who have checked the filing to be sure all papers were present.

Further evidence that these papers were filed is the accompanying PTO Notice of Recordation of Assignment document. This notes a recordation date of June 15, 2006, consistent with the filing of the papers on June 12, 2006.

Further evidence that the papers were filed is the fact that both checks mentioned in the firms PTO docket entry book were cashed by the PTO. See the accompanying papers which establish this fact.

Accordingly, more than sufficient evidence is believed to be provided, whereupon the PTO should withdraw the holding of abandonment as improper and restore this application to pending status in view of the accompanying papers, which are identical to those previously filed.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Anthony J. Zelano/


Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410


Attorney Docket No.: WEICKM-0053

Date: August 4, 2008

AJZ:pdr







UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND MILLEN, WHITE, ZELANO & BRANIGAN, P.C. DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JULY 26, 2006

PTAS MILLEN, WHITE ZELANO & BRANIGAN, P.C. ARLINGTON COURT PLAZA I SUITE 1400 2200 CLARENDON BLVD. ARLINGTON, VA 22201



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/15/2006

REEL/FRAME: 018001/0835

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ONICHTCHOUK, DARIA

DOC DATE: 02/20/2006

ASSIGNOR:

BURK, ULRIKE

DOC DATE: 02/13/2006

ASSIGNEE:

DEVELOGEN AKTIENGESELLSCHAFT

MARIE-CURIE-STR. 7

GOETTINGEN, GERMANY 370/19

SERIAL NUMBER: 10564769

FILING DATE: ISSUE DATE:

PATENT NUMBER:

TITLE: USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES

AND/OR OBESITY AND/OR METABOLIC SYNDROME

018001/0835 PAGE 2

SHARON LATIMER, EXAMINER
ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

For PTO-1595 (Rev. 08/05)
OMB No. 0651-0027 (exp. 6/30/2

10-15-06

PATENTS ONLY

RECORDATION FORM COVEI

06-21-2006

103261547

			100201347		
	To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below				
	1. Name of cor Daria ONICH Ulrike BURK Additional name(s)	of conveying party(ies) attached? Yes No	2. Name and address of receiving party(ies): Name: DeveloGen Aktiengesellschaft Street Address: Marie-Curie-Str. 7 City: Goettingen State: GERMANY		
	3. Nature of Conveyance/Execution Date(s):		Zip:37079		
	Execution Date	(s): February 20, 2006; February 13,			
	2006		Additional names(s) or address(es) attached? Yes No		
	🛭 Assignment	☐ Merger			
	☐ Security Agreement ☐ Change of Name				
	Joint Resea	rch Agreement			
	Government Interest Assignment				
	Executive Order 9424, Confirmatory License				
	☐ Other				
	4. Application or patent number(s): This document is being filed together with a new application.				
1	A. Patent Application No.(s) B. Patent No.(s)				
06/15/2 02 FC:8	10/564.769 06 MKAYPAGH 00000038 10564796 40.00 BP Additional numbers attached? [Yes No				
VE PU-U		ress to whom correspondence	6. Total number of applications and patents involved: 1		
-	concerning docus	nent should be mailed:	7. Total fee (37CFR 1.21(h) AND 3.41) \$40.00		
	Name:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C.	Authorized to be charged by credit card Authorized to be charged to deposit account Enclosed		
	Address:	Arlington Court Plaza I	None required (government interest not affecting title)		
1		Suite 1400	8. Payment Information a) Credit Card Last 4 Numbers		
		2200 Clarendon BLVD. Arlington, VA 22201	a) Credit Card Last 4 Numbers Expiration Date		
		Phone: (703) 243-6333	b) Deposit Account Number 13-3402		
		Fax: (703) 243-6410	Authorized User Name		
		E-Mail: mail@mwzb.com			
	9. Signature.	1 50908	A		
	Signature	61 Por 17	Anthony J. Zelano Date		
	Anthor	y J. Zelano			
	Name of Person	n Signing			
	Attorney Docket N	lo. WEICKM-53	Total number of pages including cover sheet, attachments, and documents 2		

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

BRANCH BANKING AND TRUST COMPANY
ARLINGTON, VIRGINIA
68-426/514

37127

6/12/2006

PATENT OFFICE FEES ACCOUNT
2200 CLARENDON BOULEVARD, SUITE 1400
ARLINGTON, VIRGINIA 22201

40.00 PAY TO THE COMMISSIONER OF PATENTS AND TRADEMARKS PRDER OF Forty & No/100 Dollars **DOLLARS** WEICKM-0053 4EMO _____ 37126 BRANCH BANKING AND TRUST COMPANY MILLEN, WHITE, ZELANO & BRANIGAN, P.C. ARLINGTON, VIRGINIA 68-426/514 PATENT OFFICE FEES ACCOUNT 2200 CLARENDON BOULEVARD, SUITE 1400 6/12/2006 ARLINGTON, VIRGINIA 22201 65.00 COMMISSIONER OF PATENTS AND TRADEMARKS Y TO THE RDER OF _ Sixty-Five & No/100 Dollars **DOLLARS** WEICKM-0053 EMO_

PATENT AND TRADEMARK OFFICE 13-10-0001 06-15-2006 FOR CREDIT TO THE U.S. TREASURY

Territe

★6312007304 MOHOVER M 54C671 69797 MOHOVER M 54C671 69797

19928294 9991)\d 99928294


PHILA, PA 66192066 24PK MACHOVIA NA 5V(B71 66797 PO312007304

~)

. .-

90000090 900134 16608

PATENT AND TRADEMARK OFFICE 13-10-0001 06-15-2006 FOR CREDIT TO THE U.S. TREASURY



```
SEQUENCE LISTING
<110> DeveloGen AG für entwicklungsbiologische Forschung
<120> Use of a DG001 secreted protein product for preventing
      and treating pancreatic diseases and/or obesity and/or
     metabolic syndrome
<130> 31160PWO GE
<140> PCT/EP2004/007917
<141> 2004-07-15
<150> EP03016169.9
<151> 2003-07-16
<160> 5
<170> PatentIn Ver. 2.1
<210> 1
<211> 1300
<212> DNA
<213> human
<220>
<221> gene
<222> (1)..(1300)
<223> nucleic acid sequence encoding the human DG001
     protein
<400> 1
ctctccctcc ctcgcccage cttcgtcctc ctggcccgct cctctcatcc ctcccattct 60
ccatttccct tccgttccct ccctgtcagg gcgtaattga gtcaaaggca ggatcaggtt 120
ccccgccttc cagtccaaaa atcccgccaa gagagcccca gagcagagga aaatccaaag 180
tggagagagg ggaagaaga gaccagtgag tcatccgtcc agaaggcggg gagagcagca 240
gcggcccaag caggagctgc agcgagccgg gtacctggac tcagcggtag caacctcgcc 300
ccttgcaaca aaggcagact gagcgccaga gaggacgttt ccaactcaaa aatgcaggct 360
caacagtacc agcagcagcg tcgaaaattt gcagctgcct tcttggcatt cattttcata 420
ctggcagctg tggatactgc tgaagcaggg aagaaagaga aaccagaaaa aaaagtgaag 480
aagtctgact gtggagaatg gcagtggagt gtgtgtgtgc ccaccagtgg agactgtggg 540
ctgggcacac gggagggcac tcggactgga gctgagtgca agcaaaccat gaagacccag 600
agatgtaaga tcccctgcaa ctggaagaag caatttggcg cggagtgcaa ataccagttc 660
caggcctggg gagaatgtga cctgaacaca gccctgaaga ccagaactgg aagtctgaag 720
cgagccctgc acaatgccga atgccagaag actgtcacca tctccaagcc ctgtggcaaa 780
ctgaccaagc ccaaacctca agcagaatct aagaagaaga aaaaggaagg caagaaacag 840
gagaagatgc tggattaaaa gatgtcacct gtggaacata aaaaggacat cagcaaacag 900
gatcagttaa ctattgcatt tatatgtacc gtaggctttg tattcaaaaa ttatctatag 960
ctaagtacac aataagcaaa aacaaaaaga aaagaaaatt tttgtagtag cgttttttaa
1020
atgtatacta tagtaccagt aggggcttat aataaaggac tgtaatctta tttaggaagt
1080
tgacttatag tacatgataa atgatagaca attgaggtaa gttttttgaa attatgtgac
1140
attttacatt aaattttttt tacatttttt gggcagcaat ttaaatgtta tgactatgta
1200
aactacttct cttgttaggt aattttttc acctagattt ttttcccaat tgagaaaaat
1260
1300
<210> 2
<211> 168
<212> PRT
<213> human
```

```
<220>
<223> amino acid sequence of human DG001 protein
<400> 2
Met Gln Ala Gln Gln Tyr Gln Gln Gln Arg Arg Lys Phe Ala Ala Ala
  1
                                      10
                                                          15
Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala
             20
Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly
         35
                              40
                                                  45
Glu Trp Gln Trp Ser Val Cys Val Pro Thr Ser Gly Asp Cys Gly Leu
     50
                          55
Gly Thr Arg Glu Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met
 65
                     70
                                          75
                                                               80
Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys Lys Gln Phe Gly
                 85
                                                          95
Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn
                                 105
            100
                                                     110
Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn
        115
                             120
                                                 125
Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu
    130
                        135
                                             140
Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys Lys Lys Lys Glu Gly
145
                    150
                                         155
                                                              160
Lys Lys Gln Glu Lys Met Leu Asp
                165
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer 5`-3
<220>
<223> mouse DG001 forward primer
<400> 3
caagtaccag ttccaggctt gg
                                                                    22
<210> 4
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer 5`-3
<220>
<223> mouse DG001 reverse primer
```

<400> 4	
gctcgcttca ggctgcc	17
<210> 5	
<210 / 3 <211 > 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: probe	
<220>	
<223> mouse DG001 Taqman probe	
<400> 5	
tgacctcaat accgccttga agaccagaac	30

•

•

.